The Society for Immunotherapy of Cancer (SITC) is pleased to announce the publication of a commentary detailing what is being described as a Crisis in Clinical Research. The clinical research pipeline is critical to ensuring continued development of novel treatments that can offer patients with cancer safe and effective options. Unfortunately, progress has slowed since the COVID-19 pandemic due to uncovered, systemic inefficiencies across critical processes.
Towards initiating discussion on how to reinvigorate clinical research, the Society for Immunotherapy of Cancer (SITC) hosted a virtual summit that characterized issues and formed potential solutions. This commentary serves to highlight the crisis facing clinical research as well as stimulate field-wide discussion on how to better serve patients into the future. Please view the full commentary here: https://jitc.bmj.com/content/12/7/e008520
